IL-2 either as a monotherapy or in combination with CTLA-4 blockade increased the proportion of less fully differentiated (CD27-CD11b-) NK cells as compared with the exhausted (CD11b+) NK cells within the tumor observed with CTLA-4 blockade alone. The gene discussed is CD27; the disease is neoplasm.